Cardiac Safety of Chronic Inhibition of the Myostatin-Activin Pathway with Bimagrumab in Healthy Older Adults

Key Points

• The aim is to evaluate the impact of bimagrumab on cardiac structure and function in older adults while inhibiting the myostatin-activin pathway.
• Conducted over six months
• Compared bimagrumab with a placebo
• Focus on healthy older adults
• Bimagrumab showed no significant effects on cardiac structure
• No impact on cardiac function compared to placebo
• Supports its use for muscle sparing during weight loss